Biotech Beyond Borders: Adapting to the New Normal

Our panel of German, American and French industry experts sparked a strong discussion on how the “new normal” for biotech, including continued scarcity of capital and the need for more efficiency in development, capital deployment and the overall healthcare system, will affect financing and growth of biotech companies in the Boston biotech cluster, and particularly in European-focused companies. Hosted by the law firm of Cooley LLP in the Back Bay.